Acorda Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Acorda Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Acorda Therapeutics Inc Strategy Report
- Understand Acorda Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Acorda Therapeutics Inc (Acorda), is a biopharmaceutical company that discovers, develops, and markets therapies for treating patients with neurological disorders. The company's portfolio encompasses marketed products for the treatment of multiple sclerosis (MS) and for the intermittent treatment of people with Parkinson’s taking levodopa or carbidopa who experience off episodes. The company sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.
Headquarters
United States of America
Address
Two Blue Hill Plaza, Pearl River, New York, 10965
Website
www.acorda.com
Telephone
1 914 3474300
No of Employees
111
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACOR (NASD)
Revenue (2021)
$118.6M
-8.1%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
36.6%
(2021 vs 2020)
Market Cap*
$470,000
Net Profit Margin (2021)
XYZ
31.0%
(2021 vs 2020)
* As of and is in US$
Acorda Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Ampyra/Fampyra: |
| Multiple Sclerosis |
| Inbrija: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company entered into a distribution and supply agreement with Chance Pharmaceuticals Co. Ltd. to provide INBRIJA in China. |
| 2022 | Contracts/Agreements | In May, the company entered a distribution and supply agreement with Biopas Laboratories to commercialize INBRIJA in Latin America. |
| 2021 | Contracts/Agreements | In July, the company entered into distribution and supply agreements with Esteve Pharmaceuticals S.A to commercialize INBRIJA 33 mg in Spain. |
Competitor Comparison
| Key Parameters | Acorda Therapeutics Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | AbbVie Inc | Bayer AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | Germany |
| City | Pearl River | Basel | Kenilworth | North Chicago | Leverkusen |
| State/Province | New York | - | New Jersey | Illinois | Nordrhein-Westfalen |
| No. of Employees | 111 | 103,605 | 72,000 | 50,000 | 99,723 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John P. Kelley | Chairman | Executive Board | 2019 | 69 |
| Ron Cohen, M.D. | Chief Executive Officer; Director; President | Executive Board | 1995 | 67 |
| Michael Gesser | Chief Financial Officer | Senior Management | 2021 | 59 |
| Kerry Clem | Chief Commercial Officer | Senior Management | 2021 | 53 |
| Denise Duca | Executive Vice President - Human Resources | Senior Management | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward